Clinical Trial Management - software & AI news

Daily news on software, AI, and companies shaping clinical trial management.

Showing 118 results
A minimalist illustration of a sleep mask over a sleeping figure, symbolizing sleep analytics.

Jul 28, 2026

HoneyNaps Expands Global CRO Services with AI-Powered Sleep Analytics Platform

HoneyNaps has taken a significant step in enhancing its capabilities in clinical trial analytics by becoming a registered Contract Research Organization (CRO) with the Korea National Enterprise for Clinical Trials (KoNECT). This registration allows the company to offer advanced AI-powered sleep data analysis services, catering to the growing needs of the global pharmaceutical, medical device, and digital health sectors.The launch of SOMNUM Clinical, HoneyNaps' AI-driven analytics service, marks
A clinical trial document and pen on a wooden desk

Jul 28, 2026

ICON to Deploy Claude AI Across Clinical Trial Lifecycle

ICON plc is set to enhance its clinical trial processes through a multi-year partnership with Anthropic, focusing on the integration of Claude AI across its operations. This initiative aims to streamline the clinical trial lifecycle, showcasing ICON's commitment to digital innovation in life sciences.Through this collaboration, ICON will leverage Anthropic's AI capabilities to advance its Orbis platform, which is designed for secure and intelligent clinical trial management. The partnership will
A patient intake form on a desk in a clinical setting

Jul 27, 2026

Reciprocal Clinical Trials

Massive Bio and Sequence Me Now have joined forces to enhance patient access to oncology clinical trials through a new partnership.This collaboration utilizes Massive Bio's AI-driven trial-matching platform to assist patients who have received genomic sequencing results in finding relevant clinical studies based on their specific cancer types and biomarkers. Sequence Me Now will feature Massive Bio on its "Find a Trial" page, while Massive Bio will create a dedicated landing page for Sequence Me
A minimalist illustration of a nasal spray and a nose, symbolizing PTSD treatment.

Jul 21, 2026

Silo Pharma expects its PTSD nasal-spray study to finish in 60 days

Silo Pharma is on track to complete its study on a nasal spray for PTSD within the next 60 days, alongside advancements in its AI platform aimed at commercial launch.Silo Pharma, a biopharmaceutical company focused on addressing mental health disorders, is progressing with its lead candidate, SPC-15, an intranasal treatment for post-traumatic stress disorder (PTSD). The company is also advancing its AI subsidiary, QwikAgents, which is preparing for a commercial launch anticipated within the next
Silhouette of a regulatory figure with a checkmark, symbolizing approval in AI adoption.

Jul 17, 2026

What Pistoia Alliance's AI Poll Reveals About Industry Readiness And Regulatory Confidence

The Pistoia Alliance's recent poll conducted during the Clinical Trials Technology Congress sheds light on the industry's readiness for AI adoption and the regulatory landscape surrounding it.In a live audience poll at the Congress, regulators from various European agencies gathered insights on the industry's sentiment toward AI in clinical research. The results highlighted significant barriers to AI adoption, including trust and regulatory uncertainty, while also indicating that the regulatory
A clinical trial participant in a consultation room holding a medical chart, with clinical materials in the background.

Jul 4, 2026

WCG Report: Only 11% of Pharma Firms Fully Implemented AI in Clinical Trials

A recent report by WCG reveals that only 11% of surveyed pharmaceutical and biotech companies have fully integrated AI and machine learning into their clinical trial processes as of late 2024. This statistic highlights a significant disconnect between the industry's discussions about AI adoption and the actual implementation on the ground, making the 2026 Clinical Research Trends and Insights Report particularly relevant.The report emphasizes four main themes: governance of AI and ML, readiness
A clinical trial participant in an examination room holding a medical chart.

Jun 30, 2026

Towards an EU clinical trials competitiveness initiative: restoring Europe's edge

Europe is facing a critical challenge in maintaining its competitiveness in clinical research as investment shifts to faster-growing regions like the U.S. and China. A coordinated and predictable trial environment could enhance patient access to innovations while upholding safety and scientific standards.Historically, Europe has been a leader in life sciences and biotechnology, contributing significantly to healthcare advancements. However, as sponsors increasingly opt for trials outside Europe,
A clinical trial document on a desk in a research office

Jun 22, 2026

ICON Selects Microsoft to Power AI-enabled Clinical Development

ICON plc has chosen Microsoft as its preferred technology partner to enhance its digital innovation and AI initiatives over the next three years. This collaboration focuses on deploying Microsoft 365 Copilot and establishing a robust cloud, data, and AI infrastructure to scale ICON's Orbis AI platform.Through the Orbis platform, ICON is integrating an intelligence layer that connects expertise, data, and AI throughout the clinical trial lifecycle. This approach aims to improve various aspects of
Stylized twin figure representing Computational Twins with simulation waves

Jun 16, 2026

Faculty Introduces the Frontier Life Sciences Developer Studio, Giving Clinical Trial Teams a Faster Path to Simulation-Driven Decision Intelligence

Faculty has unveiled the Frontier Life Sciences Developer Studio, a specialized environment aimed at enhancing the efficiency of clinical trial simulations through advanced Computational Twins (CTs).Launched on June 16, 2026, the Frontier Life Sciences Developer Studio is designed to streamline the development, validation, and deployment processes for decision engineers in the life sciences sector. By facilitating rapid iteration and deployment of Computational Twins, this platform aims to impro
A minimalist representation of a drug capsule and KRAS protein structure.

Jun 14, 2026

How Astellas’ AI-Driven Clinical Overhaul and KRAS Bet Will Impact Astellas Pharma (TSE:4503) Investors

Astellas Pharma is transforming its drug development strategy by integrating AI tools and bringing clinical operations in-house, particularly as it advances its KRAS-targeting candidate, setidegrasib, into a phase 3 trial for pancreatic cancer. This strategic pivot aims to enhance research and development efficiency, positioning the company to compete in the crowded oncology landscape while also exploring opportunities in gene therapy and targeted protein degradation.Astellas' shift to AI-driven
A minimalist representation of a clinical trial document with a checkmark in a dark color scheme.

Jun 12, 2026

Astellas taps AI to reshape clinical programs as rising stars emerge

Astellas Pharma is actively transforming its drug development strategy by internalizing clinical operations and leveraging AI technologies to enhance efficiency.The company, under the leadership of Tadaaki Taniguchi, is moving away from outsourcing by establishing a dedicated team to manage the entire lifecycle of each asset. This shift allows Astellas to conduct trials with its own research teams, significantly speeding up processes and improving communication across its global operations. AI p
A minimalist illustration of a lung and a clinical trial document on a solid background.

Jun 4, 2026

Massive Bio, Optellum Partner on Early Detection, Clinical Trial Access for Lung Cancer

Massive Bio and Optellum have joined forces to enhance early detection and clinical trial access for patients with non-small cell lung cancer (NSCLC), addressing a critical gap in cancer care.This partnership aims to bridge the disconnect between high-risk patients identified through routine imaging and their enrollment in clinical trials. Despite lung cancer being the leading cause of cancer-related deaths globally, many high-risk patients never participate in trials, which could significantly